loader2
Partner With Us NRI

Jagsonpal Pharmaceuticals Ltd share Price Today

Company details

344.50
352.85
273.60
514.85
6M Return -9.43%
1Y Return -2.00%
Mkt Cap.(Cr) 917.93
Volume 7,233
Div Yield 1.43%
OI
-
OI Chg %
-
Volume 7,233

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Jagsonpal Pharmaceuticals announced Q2FY24 & H1FY24 results:

  • Q2FY24:
    • Revenues: Rs 57.8 crore, showing a decrease of 4.5% compared to Q2FY23.
    • Operating EBITDA: Rs 12.6 crore.
    • EBITDA Margin: 21.7%, an increase of 100 basis points (bps) from Q2FY23.
    • ESOP Cost: Rs 4.2 crore.
    • PAT (Profit After Tax): Rs 7.5 crore, marking a decrease of 27.9% compared to Q2FY23.
  • H1FY24:
    • Revenues: Rs 118.0 crore, showing a decrease of 2.6% compared to H1FY23.
    • Operating EBITDA: Rs 25.4 crore, reflecting a 17.6% increase from H1FY23.
    • EBITDA Margin: 21.5%, an increase of 360 bps from H1FY23.
    • ESOP Cost: Rs 8.4 crore.
    • PAT (Profit After Tax): Rs 15.0 crore, reflecting a 12.8% increase compared to H1FY23.

Commenting on the Company’s performance, Manish Gupta, Managing Director stated, “We had a satisfactory outcome for the period, as the performance should be seen in the context of challenging external operating environment with slowing industry coupled with internal challenges in our flagship products - hyper-competition with 75 competitors in Divatrone®(Dydrogesterone) and availability of counterfeits products in Indocap SR® (Indomethacin).

Overall, we maintained our profitability for the quarter, with 100 bps improvement in operating margins, even as we reported a 4.5% decline in revenues. We maintained cash balance at Rs 125 crore despite dividend payout of Rs 13.1 crore during the quarter.

We introduced certain structural initiatives including strengthening anti-counterfeit packing for our key brands. These, along with proposed new product launches gives us the confidence of returning to top-line growth from Q4FY24 onwards.”

Result PDF

View Other Company Results

Jagsonpal Pharmaceuticals Ltd shares SWOT Analysis

Strengths (5)

  • Company with No Debt
  • Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
  • Book Value per share Improving for last 2 years

Weakness (6)

  • Negative profit growth, promoters decreasing shareholding QoQ
  • Degrowth in Revenue and Profit
  • Degrowth in Quarterly Revenue and Profit in Recent Results(YoY)

Opportunity (1)

  • RSI indicating price strength

Threats (3)

  • Promoter decreasing their shareholding
  • High PE (PE > 40)
  • Increasing Trend in Non-Core Income

Resistance and support

R1 357.2
R2 363.2
R3 371.6
Pivot

348.77

S1 342.7
S2 334.3
S3 328.3
EMA SMA
336.4
328.0
336.5
350.7
339.9
314.8
333.2
376.7
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
MANISH MAHESH GUPTA Bulk Purchase 2022-02-25 239.32 225067 NSE
J & P INVESTMENTS PARTNERSHIP Bulk Sell 2022-02-25 239.32 225737 NSE
MANISH MAHESH GUPTA Bulk Purchase 2022-02-24 235.33 200433 NSE
Name Category Shares
RAJPAL SINGH KOCHHAR PROMOTER 4.58%
INFINITY HOLDINGS PROMOTER 25.01%
ARESKO PROGRESSIVE PRIVATE LIMITED PROMOTER 20.18%
INFINITY HOLDINGS SIDECAR I PROMOTER 17.99%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Jagsonpal Pharmaceuticals Ltd Stocks COMPARISON

Financials( in Cr) Jagsonpal Pharmaceuticals Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Zydus Lifesciences Ltd Divis Laboratories Ltd
Price 347.20 1,519.30 1,466.20 1,071.05 4,012.05
% Change -1.12 -1.40 1.66 -1.59 -0.11
Mcap Cr 917.93 364,530.97 118,376.15 107,772.69 106,507.49
Revenue TTM Cr 236.71 43,885.68 15,790.60 17,237.40 7,767.51
Net Profit TTM Cr 26.72 8,560.84 2,513.47 1,997.30 1,823.38
PE TTM 37.85 39.42 27.36 28.41 77.12
1 Year Return -2.00 62.07 58.52 111.57 22.88
ROCE 23.48 16.79 14.76 16.25 19.30
ROE 18.32 16.46 10.66 14.05 14.89
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 158.89 Cr FV: 5.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 45,096.27 -30,251.22
LAST 3M 104,708.81 -33,860.28
LAST 6M 170,310.47 50,918.71
LAST 12M 264,009.23 128,860.46
Board of Jagsonpal Pharmaceuticals recommends final dividend

May 21, 2024 l BSE Announcement

Jagsonpal Pharmaceuticals Limited - Dividend

May 21, 2024 l NSE Announcement

NSE Board Meetings Forthcomming

May 20, 2024 l NSE Board Meetings Forthcomming

Date Action Type Ratio
Aug 21, 2023 Dividend 100

Jagsonpal Pharmaceuticals Ltd Information

Stock PE (TTM)
37.85
Promoter Holding
68.09%
Book Value
64.1222
ROCE
23.48%
ROE
18.32%
Description
  • Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company. The Company`s R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. It`s R&D activities are geared towards development of new product technologies which can be commercialised in future. It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia. In the fiscal 2001, the company`s sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity.

Registered Address

T-210 J, Shahpur Jat, New Delhi, New Delhi, 110049

Tel : 91-011-46181100/46109900
Email : skmata:jagsonpal.com; cs:jagsonpal.com
Website : http://www.jagsonpal.com
Registrar

MCS Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 507789
NSE Code : JAGSNPHARM
Book Closure Date (Month) :
BSE Group : B
ISIN : INE048B01027

FAQ’s on Jagsonpal Pharmaceuticals Ltd Shares

You can buy Jagsonpal Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Jagsonpal Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 22, 2024 11:14 AM the closing price of Jagsonpal Pharmaceuticals Ltd was Rs.347.20.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 22, 2024 11:14 AM, the market cap of Jagsonpal Pharmaceuticals Ltd stood at Rs. 917.93.

The latest PE ratio of Jagsonpal Pharmaceuticals Ltd as of May 22, 2024 11:14 AM is 37.85

The latest PB ratio of Jagsonpal Pharmaceuticals Ltd as of May 22, 2024 11:14 AM is 0.18

The 52-week high of Jagsonpal Pharmaceuticals Ltd share price is Rs. 514.85 while the 52-week low is Rs. 273.60

Download App

Download Our App

Play Store App Store
market app